NICE issues guidance on sepsisBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7469.758-a (Published 30 September 2004) Cite this as: BMJ 2004;329:758
- Susan Mayor
The National Institute for Clinical Excellence (NICE) has recommended in new guidance that patients with severe sepsis should be treated with drotrecogin alfa (activated) only under the supervision of intensive care specialists with experience in managing the condition.
NICE, which provides national guidance on treatments and care used by the NHS in England and Wales, recommended that intensive care units in NHS hospitals should define the clinical circumstances in which drotrecogin alfa (activated) is to be used and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial